Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant atezolizumab vs observation in high‑risk muscle‑invasive urothelial carcinoma after surgery
jRCT2080223033Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in urothelial carcinoma (MIBC) comparing Atezolizumab with Observation (2 arms). Primary endpoint: Disease-free survival (DFS). Started Dec 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
urothelial carcinoma (MIBC)
Beyond the preview
Go deeper on jRCT2080223033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223033.